Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones

Journal of Virology

Volumn 88, Issue 21, 2014, Pages 12233-12241

  Smith, Scott A ^a   Ruklanthi de Alwis, A ^b   Kose, Nurgun ^a   Jadi, Ramesh S ^b   de Silva, Aravinda M ^b   Crowe, James E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; MONOCLONAL ANTIBODY; VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; CELL TRANSFORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS REACTION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS ATTACHMENT; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN; B LYMPHOCYTE; IMMUNOLOGY; ISOLATION AND PURIFICATION; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS;

EID: 84907979176     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00247-14     Document Type: Article

References (23)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http: //dx.doi.org/10.1038/nature12060.
2. Gubler DJ. 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:100-103. http://dx.doi.org/10.1016/S0966-842X(01)02288-0.
3. Halstead SB, O'Rourke EJ. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741. http://dx.doi.org/10.1038/265739a0.
4. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139. http://dx.doi.org/10.1016/j.chom.2010.01.004.
5. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769-7773. http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001.
6. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360 http://dx.doi.org/10.1016/j.virol.2007.05.042.
7. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837. http://dx.doi.org/10.1128/JVI.00606-08.
8. Lin B, Parrish CR, Murray JM, Wright PJ. 1994. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202:885-890. http://dx.doi.org/10.1006/viro.1994.1410.
9. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826. http://dx.doi.org/10.1128 /JVI.00432-07.
10. Wahala WM, de Silva AM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374-2395. http://dx.doi.org/10.3390 /v3122374.
11. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113. http://dx.doi.org/10.1016/j.virol.2009.06.037.
12. Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 viruslike particle antigens. PLoS One 4:e4991. http://dx.doi.org/10.1371 /journal.pone.0004991.
13. Messer WB, de Alwis R, Yount B, Royal S, Huynh J, Smith SA, Crowe JE, Doranz B, White LJ, Sariol CA, de Silva AM, Baric RS. 2014. Dengue virus envelope protein domain I/II hinge determines long-lived serotypespecific dengue immunity. Proc. Natl. Acad. Sci. U. S. A. 111:1939-1944. http://dx.doi.org/10.1073/pnas.1317350111.
14. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012 Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 109:7439-7444 http://dx.doi.org/10.1073/pnas.1200566109.
15. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE, Jr. 2012. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J. Virol. 86:2665-2675. http://dx.doi.org/10.1128/JVI.06335-11.
16. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5:e1188. http://dx.doi.org/10.1371/journal.pntd.0001188.
17. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Crossreacting antibodies enhance dengue virus infection in humans. Science 328: 745-748. http://dx.doi.org/10.1126/science.1185181.
18. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx .doi.org/10.1016/j.chom.2010.08.007.
19. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139-183. http://dx.doi.org/10.1126/scitranslmed.3003888.
20. Fibriansah G, Tan J, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Harris E, de Silva A, Crowe JE, Jr, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6:358-371. http://dx.doi.org/10.1002/emmm.201303404.
21. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE, Jr. 2013. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J. Infect. Dis. 207:1898-1908. http://dx.doi.org/10.1093/infdis/jit119.
22. Kraus AA, Messer W, Haymore LB, de Silva AM. 2007. Comparison of plaque-and flow cytometry-based methods for measuring dengue virus neutralization. J. Clin. Microbiol. 45:3777-3780. http://dx.doi.org/10.1128/JCM.00827-07.
23. Lambeth CR, White LJ, Johnston RE, de Silva AM. 2005. Flow cytometry-based assay for titrating dengue virus. J. Clin. Microbiol. 43:3267-3272 http://dx.doi.org/10.1128/JCM.43.7.3267-3272.2005.